Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Andrea VarroneDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Services, BioClinicum, J4-14, Akademiska Stråket 1, 17176 Solna, Sweden.ORCID 0000-0001-8281-4435
Vasco C SousaDepartment of Clinical Neuroscience, Division of Imaging Core Facilities, Karolinska Institutet, Stockholm, Sweden, BioClinicum, J5, Akademiska Stråket 1, 17176 Solna, Sweden.ORCID 0000-0002-0086-6168
Charles S ElmoreIsotope Chemistry, Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden.ORCID 0000-0001-7434-8307
Dan SunnemarkOffspring Biosciences, Forskargatan 20 J, 15136 Södertälje, Sweden.ORCID 0000-0002-6084-2678
Dinahlee Saturnino GuarinoDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, 1012, 231 S. 34th Street, Philadelphia, PA 19104, USA.ORCID 0009-0003-3841-1825
Sjoerd J FinnemaTranslational Sciences, Neuroscience & Ophthalmology Discovery Research, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA.ORCID 0000-0002-4972-3627
Magnus SchouPrecision Medicine Diagnostic Development and HBS Science, AstraZeneca R&D Oncology, AstraZeneca J4:14, BioClinicum, Akademiska Stråket 1, 17176 Solna, Sweden.
Funding
Medicinal Chemistry CoreU19NS110456 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI ROBERT H MACH · 2019 to 2026
$44.1M
Michael J Fox Foundation for Parkinson Research 10908NINDS NIH HHS U19 NS110456Swedish Parkinson Foundation (Parkinsonfonden) 1268/20
6 · The paper itself
Abstract
The molecular imaging of α-synuclein (α-syn) pathology in Parkinson's disease (PD) and related movement disorders is a clinically unmet need. The aim of this study was to discover and characterize in vitro a radioligand for imaging α-syn pathology. A library of 78 small molecules was developed and screened using recombinant α-syn fibrils and brain homogenates from Alzheimer's disease (AD) donors. The selection criteria were as follows:
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Development and In Vitro Characterization of [ · full record | Socratic